Law360 (September 28, 2020, 5:55 PM EDT) -- Teva is unable to dodge a $110 million case claiming that it botched the marketing and sale of the muscle relaxant Amrix, after a Virginia federal judge found the suit at this point had sufficient allegations that Teva and its affiliates breached a contract.
On Friday, U.S. District Judge M. Hannah Lauck denied motions from Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA Inc., Teva Pharmaceuticals International GmbH and Cephalon Inc. to dismiss the breach-of-contract suit from E. Claiborne Robins Co. Robins had developed Amrix, but sold off its rights to the drug to a company that eventually became a Teva subsidiary...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!